How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

2,179 results for

Hepatotoxic Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2121. The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

prior to study entry. Prior Medication: Excluded: Any prior antiretroviral therapy except for ddI, ddC, 3TC or ZDV (for ZDV, as specified in inclusion criteria). Previous therapy with agents with significant systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start. Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole within 2 weeks prior to starting indinavir. Any other prior therapy (...) diagnosed AIDS defining opportunistic infection requiring acute therapy at time of enrollment. Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive days). Signs and symptoms of bilateral peripheral neuropathy >= grade 2 at the time of screening. Inability to tolerate oral medication. Any other clinical conditions that in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements. Concurrent Medication: Excluded: Therapy

1999 Clinical Trials

2122. Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer

). Recruitment status was: Active, not recruiting First Posted : August 23, 2004 Last Update Posted : December 18, 2013 Sponsor: Leiden University Medical Center Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II trial to compare (...) . The second group receives intravenous mitoxantrone every 3 weeks for a maximum of 8 courses. Concomitant therapy with hepatotoxic or nephrotoxic drugs (e.g., NSAIDs) or corticosteroids (even as antiemetics) is not permitted in either group. Radiotherapy is allowed provided no more than 50% of the bone marrow is irradiated and at least 1 indicator lesion is unirradiated. Patients who complete therapy are followed every 3 months until disease progression. PROJECTED ACCRUAL: 60 patients will be accrued over

1999 Clinical Trials

2123. Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

by serum creatinine level < 2.0 mg/dL. Normal TSH or adequately controlled thyroid function. If the patient is a woman, she is using a definitive method of birth control in consultation with her physician, or is surgically sterile or post-menopausal. Exclusion criteria: Use of systemic corticosteroids within 6 months of entry. Current use of any drug known to be hepatotoxic, any drug (other than the study drugs) known to have or suspected of having therapeutic activity in hepatitis C or of any (...) or intravenous drug abuse within the previous 1 year. Chronic use of methadone. Patients who are poor medical risk or who have any non-malignant systemic disease that, in the opinion of the investigator, would make it unlikely that the patient could complete the protocol. Patients with a history of severe depression that required either hospitalization or electroshock therapy; or depression associated with suicide attempt. Patients with significant pre-existing cardiac or pulmonary disease. Any indication

2002 Clinical Trials

2124. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. (PubMed)

Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. Dopamine receptor antagonists, particularly haloperidol, have been the most effective medications in currently available double-blind placebo-controlled studies for treating the disruptive behaviors often associated with pervasive developmental disorder (PDD). The rationale for trying risperidone in this population includes its dopamine-blocking activity; its seemingly lower incidence (...) remained on risperidone for over 2 years, but 1 patient developed hepatotoxicity and another developed withdrawal dyskinesia, similar to her prior experience with haloperidol. Overall, 5 of the 6 patients derived significant clinical benefits from risperidone. Pharmacologic alternatives for treating behavioral symptoms in PDD are need, and risperidone may be a promising possibility.

1997 Journal of Child and Adolescent Psychopharmacology

2125. A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. (PubMed)

A double-blinded, randomized trial of hydrocortisone in acute hepatic failure. The Acute Hepatic Failure Study Group. The Acute Hepatic Failure Study Group (AHFSG) has conducted a double-blinded, randomized evaluation of hydrocortisone in patients with acute hepatic failure. From July 1975 through August 1978, a 38-month period, 18 medical centers in the United States and one in Canada participated in this trial. A total of 64 patients were accessed and found eligible to participate (...) in the study; two of them were subsequently eliminated from our analysis. Eighteen patients received placebo; 23 received 400 mg hydrocortisone per day, and 21 patients were administered 800 mg hydrocortisone per day. We did not observe any therapeutic effect of hydrocortisone, and the survival rates for placebo versus 400 mg and versus 800 mg hydrocortisone per day were 22%, 9%, and 24%, respectively. Fulminant hepatitis associated with drug hepatotoxicity or non-A, non-B hepatitis seemed to have a worse

1991 Digestive diseases and sciences

2126. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. (PubMed)

in medical practice. After 6 weeks on the American Heart Association Step 1 Diet, a total of 8,245 patients were randomly assigned to 48 weeks of treatment with diet and placebo or lovastatin at dosages of 20 or 40 mg once a day or 20 or 40 mg twice a day. All adverse events were monitored, with particular attention to evaluation of liver and muscle. Liver transaminase elevations suggestive of possible hepatotoxicity, defined as successive elevations in either aspartate transaminase or alanine

1991 The American journal of medicine

2127. A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 50 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: Other medically indicated vaccinations, provided they are administered at least 2 weeks before or after any study injection. Alcohol use limited to 1 oz per day of 100 proof. Patients must have: HIV infection without evidence (...) of AIDS. CD4 count > 500 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Current evidence of underlying lung or liver disease. Suspected or diagnosed allergy to any vaccine component. Medical contraindication to protocol participation. Undergoing allergy skin testing or desensitization. Concurrent Medication: Excluded: Antiretroviral therapy (unless clinically indicated and with approval of investigator). Immunosuppressive

1999 Clinical Trials

2128. A Study of Dideoxycytidine in HIV-Infected Patients

entry will be excluded. Patients with fever > 102 degrees F at study entry will be excluded. Prior Medication: Excluded: Chronic systemic medications. Any other experimental drug within 2 weeks of study entry. Drugs with known nephrotoxic or hepatotoxic effects within 2 weeks of study entry. Drugs known to cause neutropenia within 2 weeks of study entry. Rifampin or rifampin derivatives, phenytoin, or barbiturates within 2 weeks of study entry. Any other medication except oral nonabsorbable (...) this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Prior Medication: Allowed: Oral nonabsorbable antifungal agents. Exclusion Criteria Active drug or alcohol abuse. Co-existing Condition: Patients with fever > 102 degrees F at study

1999 Clinical Trials

2129. The Safety and Effectiveness of Zidovudine in the Treatment of HIV-Infected Children With Mild to Moderate Symptoms

manifested by nephrotic syndrome without evidence of renal failure, two or more episodes of herpes stomatitis or one or more episodes of herpes zoster within a 1 year period; plus at least one of the following: hypergammaglobulinemia, depression in the CD4+ cells to = or < 500/mm3, decreased helper/suppressor ratio < 1.0, depressed in vitro mitogen response to at least one antigen/mitogen. Concurrent Medication: Excluded: Hepatotoxic drugs. Steroids for lymphocytic interstitial pneumonitis (LIP (...) that symptomatic HIV-infected children may also benefit from specific antiviral therapy. Children who participate in the study are evaluated at a hospital outpatient clinic and are under the care of a specialist in pediatrics. Of the children who participate in the study, half receive AZT syrup and half receive a placebo (sugar solution). The investigator does not know which medication each child receives as this is decided by a random process. The children take the medication in a strawberry-flavored clear

1999 Clinical Trials

2130. A Study of Nevirapine Used Alone or in Combination With AZT in HIV-1-Infected Children

. Dicumarol, warfarin, and other anticoagulants. Digitoxin. Valproic acid. Tolbutamide. Doxycycline. Chloramphenicol. Isoniazid. Phenobarbital and other barbiturates. Hepatotoxic drugs. Patients with prior participation in this trial are excluded. Prior Medication: Excluded: More than 6 weeks of prior zidovudine (AZT) therapy or more than 6 weeks of any other antiretroviral therapy. Excluded within 7 days prior to study entry: AZT (in monotherapy groups only). Excluded within 4 weeks prior to study entry (...) Ages Eligible for Study: up to 17 Years (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: IV gammaglobulin therapy. Medications for PCP prophylaxis (e.g., TMP / SMX, dapsone, aerosolized and IV pentamidine). Fluconazole. Patients must have: HIV infection. A positive Polymerase Chain Reaction (PCR) is not acceptable as the sole evidence of HIV infection. Three out of five children in each age and dose group must have

1999 Clinical Trials

2131. A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed with caution for Study A: Hepatotoxic drugs. Patients in Study A must have: Hemophilia with no symptoms for AIDS. Most patients will have well-established factor 8 or 9 deficiency. However, patients with other coagulation diseases, such as factor 5 deficiency, and von Willebrand disease, will also be acceptable for the study. Wives in Study B are included even if they are known to be seropositive (...) of infected hemophilic patients have become infected during long-term sexual relationships. Transmission of the virus does not occur during casual family contact. This study will aid in determining if therapy influences the transmission of HIV, because the wives of hemophiliacs generally have no risk for HIV infection other than sexual contact with their spouse. Study A: Patients selected for the study are randomly assigned to placebo (inactive medication) or ZDV taken every 4 hours while the patient

1999 Clinical Trials

2132. A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects

. Hypertension-inducing, nephrotoxic, or hepatotoxic drugs. Opiates. Drugs known to cause photosensitivity. Prior Medication: Excluded within 1 month prior to study entry: AZT, ddI, ddC, d4T, or any other antiretroviral medication. Interferon or other immunomodulating drugs. Cytotoxic chemotherapy. Preparations known to contain hypericin. Excluded within 3 months prior to study entry: Ribavirin. Hyperforate (500 mg tablets or ampules for IV injection) manufactured by Kline. Psychotonin M Alcohol Extract (...) and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Required: PCP prophylaxis. Allowed: Rifabutin, ketoconazole, fluconazole

1999 Clinical Trials

2133. A Study of Zidovudine in HIV-Infected Patients With Kidney Problems

receive AZT every 4 hours, including in the middle of the night, and keep a diary of the times they take AZT, as well as of the use of other medications, tobacco, or alcohol. A return appointment is made for 8-15 days later. On that day, patients again receive AZT by mouth, and blood tests and urine samples are again taken. Patients who are receiving hemodialysis participate in 1 additional day of pharmacokinetic studies to be arranged during one hemodialysis session. Patients on Continuous Ambulatory (...) (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: Symptomatic therapy such as analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy. Aerosolized pentamidine. Discouraged: - Sucralfate or antacids. However if these medications are essential for the patient's management, they should not be given within 8 hours before or 2 hours after the scheduled pharmacokinetic study

1999 Clinical Trials

2134. A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

medication felt to be immunomodulatory or felt to exhibit significant hepatotoxicity or hematologic or renal toxicity by study investigators. Prior Medication: Excluded within 6 weeks of study entry: Systemic steroids. Cytotoxic immunosuppressive medications. Any systemic experimental anti-HIV drug such as dideoxycytidine (ddC), foscarnet, ribavirin, isoprinosine, or zidovudine (AZT). Any other medication felt to be immunomodulatory or felt to exhibit significant hepatotoxicity or hematologic or renal (...) . Concurrent Medication: Allowed: Systemic medications not listed in the Exclusion Concurrent Medications field considered necessary for the patient's medical management and which would not interfere with the study may be used, but such use must be documented. Exclusion Criteria Concurrent Medication: Excluded: Systemic steroids. Cytotoxic immunosuppressive medications. Any systemic experimental anti-HIV drug such as dideoxycytidine (ddC), foscarnet, ribavirin, isoprinosine, or zidovudine (AZT). Any other

1999 Clinical Trials

2135. A Phase I, Dose-Escalating Safety and Tolerance Study of sCD4-PE40 in HIV-Infected Persons

, histoplasmosis, or CMV or nonopportunistic diseases including liver disease, renal disease, or orthostatic hypotension) at time of study entry. Active pulmonary disease. Chronic active hepatitis B surface antigenemia or unstable hepatitis C. Current diagnosis of malignancy for which systemic therapy would be required during the study. Inadequate intravenous access. Concurrent Medication: Excluded: Hepatotoxic agents. Other antiretroviral or immunomodulator agents (including but not limited to AZT, ddI, ddC (...) Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: PCP prophylaxis with aerosolized pentamidine, trimethoprim / sulfamethoxazole, or dapsone. Clotrimazole troches or nystatin oral suspension for oral candidiasis. Acyclovir (up to 1000 mg/day for 10 days) for herpes lesions. Erythropoietin. Patients must have: Documented HIV infection by ELISA confirmed by a second method. If a prior diagnosis of AIDS has not been established by CDC

1999 Clinical Trials

2136. (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) Versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

. Unwilling or unable to sign informed consent. Prior Medication: Excluded: Zidovudine (AZT), dideoxycytidine (ddC), or any other antiretroviral nucleoside analog. Excluded within 90 days of study entry: Any experimental drug including fluconazole, ganciclovir, foscarnet, erythropoietin, or ribavirin. Excluded within 90 days of study entry: Drugs that have caused significant nephrotoxicity or significant hepatotoxicity. Drugs that could cause peripheral neuropathy including phenytoin, hydralazine (...) , you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: Aerosolized pentamidine (300 mg once every 4 weeks) for Pneumocystis carinii pneumonia (PCP) prophylaxis. Neuroleptics, benzodiazepines, or antidepressants

1999 Clinical Trials

2137. Phase I Study of Weekly Oral VP-16 for AIDS-Associated Kaposi's Sarcoma

. Concurrent Medication: Excluded: Therapy with potentially myelosuppressive, hepatotoxic, or nephrotoxic drugs for an opportunistic infection. Patients with the following are excluded: Active opportunistic infection not specifically allowed. Ongoing therapy, including maintenance therapy, for an opportunistic infection with potentially myelosuppressive, hepatotoxic, or nephrotoxic drugs. Concurrent neoplasm not specifically allowed. Significant neurologic, cardiac, or liver disease. Prior Medication (...) . VP-16 is an antitumor agent. Previous problems with VP-16 include the route of administration and the toxicities. VP-16 has been given intravenously for 3 consecutive days in a 21-day cycle for lung cancer and testicular cancer. VP-16 has also been used in lymphoma therapy. Oral VP-16 would eliminate the need for an intravenous catheter and so a patient could avoid the pain, inconvenience, and potential complications associated with medications administered intravenously. The relative ease

1999 Clinical Trials

2138. A Phase I Dose Escalation Study of Synthetic Hypericin in HIV-Infected Patients With Less Than 300 CD4 Lymphocytes

Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed: Prophylaxis for Pneumocystis carinii pneumonia (required for patients with CD4+ < 200). Symptomatic treatment with analgesics, antihistamines, antiemetics, antidiarrheal agents, or other supportive therapy. Short courses (< 10 days) with ketoconazole or fluconazole for oral candidiasis or acyclovir for herpes lesions. Topical medications (...) such as clotrimazole troches or nystatin suspensions. Concurrent Treatment: Allowed: Blood transfusions. Patients must have HIV infection with CD+4 lymphocyte count of < 300 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded. Kaposi's sarcoma requiring systemic therapy. Concurrent Medication: Excluded: Continued use of opiates or drugs known to induce photosensitivity. Patients with the following are excluded: Active or chronic opportunistic

1999 Clinical Trials

2139. A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)

, glutethimide, gold, hydralazine, isoniazid, metronidazole, vincristine, and nitrofurantoin. Excluded within 4 weeks of study entry: Drugs that have caused significant nephrotoxicity or significant hepatotoxicity (as defined by transaminases). Concurrent Treatment: Excluded: Transfusion dependent. Patients are excluded if unwilling or unable to sign informed consent. Prior Medication: Excluded: Zidovudine (AZT). Dideoxycytidine (ddC). Any other nucleoside antiretrovirals. Positive antibody to HIV using any (...) in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Allowed

1999 Clinical Trials

2140. The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children

-existing Condition: Patients with the following conditions or symptoms are excluded: AIDS or class P-2B, D, or E symptomatic infection. Concurrent Medication: Excluded: Hepatotoxic or neurotoxic drugs, immunosuppressants, or antiseizure medication. Ketoconazole, fluconazole, and acyclovir for prophylaxis. Immunomodulators (other than IVIG). Experimental drugs. Cohort A patients: AZT for clinical indications. Prior Medication: Excluded: Other antiretroviral agents (including didanosine (ddI (...) a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 3 Months to 17 Years (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria Concurrent Medication: Recommended: Prophylaxis for Pneumocystis carinii pneumonia. Allowed: Aerosol ribavirin for short-term treatment of acute respiratory

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>